论文部分内容阅读
神经肽促生长素抑制素(SRIF)对癌症的作用尚未阐明。近期对各种正常和肿瘤组织中SRIF受体的研究表明,这种作用涉及直接和间接途径。本文阐述了肿瘤形成过程中涉及SRIF的多种生物学机制、其治疗潜能以及目前SRIF类似物的局限性。
The role of neuropeptide somatostatin (SRIF) in cancer has not been elucidated. Recent studies of SRIF receptors in various normal and tumor tissues have shown that this effect involves both direct and indirect pathways. This article describes various biological mechanisms involved in the development of tumors that involve SRIF, their therapeutic potential, and the limitations of current SRIF analogues.